Anja Rogler

527 total citations
17 papers, 413 citations indexed

About

Anja Rogler is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anja Rogler has authored 17 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 9 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anja Rogler's work include Bladder and Urothelial Cancer Treatments (7 papers), Urinary and Genital Oncology Studies (4 papers) and Fibroblast Growth Factor Research (3 papers). Anja Rogler is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Urinary and Genital Oncology Studies (4 papers) and Fibroblast Growth Factor Research (3 papers). Anja Rogler collaborates with scholars based in Germany, Switzerland and United Kingdom. Anja Rogler's co-authors include Arndt Hartmann, Robert Stoehr, Peter J. Wild, Reto Huggenberger, Michael Detmar, Cédric Poyet, Robert Stöhr, Vivianne I. Otto, Filip Roudnicky and Maurizio Provenzano and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and American Journal Of Pathology.

In The Last Decade

Anja Rogler

17 papers receiving 411 citations

Peers

Anja Rogler

SURGE

IMMUN

ONCOL

Allen B. Tu United States

Ryusuke Watanabe Japan

Otávio Alberto Curioni Brazil

Ewa Kurzejamska Sweden

Laura Pavan Italy

Baojun Huang China

Shuya Kaneko Japan

Jessica Schreiter United States

Yasuyuki Shigematsu Japan

Yingjiao Cao China

Allen B. Tu United States

Anja Rogler

80 ×0.4

SURGE

100 ×0.6

64 ×0.7

IMMUN

139 ×2.0

ONCOL

54 ×0.9

Citations per year, relative to Anja Rogler Anja Rogler (= 1×) peers Allen B. Tu

Countries citing papers authored by Anja Rogler

Since Specialization

Citations

This map shows the geographic impact of Anja Rogler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja Rogler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja Rogler more than expected).

Fields of papers citing papers by Anja Rogler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja Rogler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja Rogler. The network helps show where Anja Rogler may publish in the future.

Co-authorship network of co-authors of Anja Rogler

This figure shows the co-authorship network connecting the top 25 collaborators of Anja Rogler. A scholar is included among the top collaborators of Anja Rogler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja Rogler. Anja Rogler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Goebell, Peter J., Christian Doehn, Norbert Marschner, et al.. (2019). Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. Oncology Research and Treatment. 42(1-2). 57–66. 2 indexed citations

Boegemann, Martin, Jens Bedke, Martin Schostak, et al.. (2019). Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology. 37(15_suppl). 4574–4574. 2 indexed citations

Giedl, Johannes, Anja Rogler, Andreas B. Wild, et al.. (2016). TERT Core Promotor Mutations in Early-Onset Bladder Cancer. Journal of Cancer. 7(8). 915–920. 25 indexed citations

Rogler, Anja, Johannes Giedl, Robert Stoehr, et al.. (2015). Functional analyses and prognostic significance of SFRP1 expression in bladder cancer. Journal of Cancer Research and Clinical Oncology. 141(10). 1779–1790. 15 indexed citations

Rogler, Anja, Ramona Erber, Robert Stoehr, et al.. (2014). Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology. 66(5). 639–649. 38 indexed citations

Rogler, Anja, Johannes Giedl, Arif B. Ekici, et al.. (2014). Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study. BMC Cancer. 14(1). 214–214. 13 indexed citations

Giedl, Johannes, Nadine T. Gaisa, Anja Rogler, et al.. (2014). Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.. PubMed. 7(4). 1708–13. 8 indexed citations

Rogler, Anja, Eileen Socher, Elke Nolte, et al.. (2013). Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.. PubMed. 6(10). 1984–98. 15 indexed citations

Roudnicky, Filip, Cédric Poyet, Peter J. Wild, et al.. (2013). Abstract 3893: Endocan is upregulated on tumor vessels in invasive bladder cancer and mediates VEGF-A-induced angiogenesis.. Cancer Research. 73(8_Supplement). 3893–3893. 1 indexed citations

10.

Rau, Tilman T., Anja Rogler, Grzegorz Burnat, et al.. (2013). Gastrin mediated down regulation of ghrelin and its pathophysiological role in atrophic gastritis.. PubMed. 64(6). 719–25. 12 indexed citations

11.

Rau, Tilman T., Anja Rogler, Andreas Jung, et al.. (2012). Methylation-Dependent Activation of CDX1 through NF-κB. American Journal Of Pathology. 181(2). 487–498. 18 indexed citations

12.

Roudnicky, Filip, Cédric Poyet, Peter J. Wild, et al.. (2012). Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis. Cancer Research. 73(3). 1097–1106. 146 indexed citations

13.

Keck, Bastian, Robert Stoehr, Sven Wach, et al.. (2011). Das plasmazytoide und mikropapilläre Urothelkarzinom. Der Urologe. 50(2). 217–220. 5 indexed citations

14.

Rogler, Anja, Ferdinand Hofstaedter, Andrea Tannapfel, et al.. (2011). P53 Codon 72 (Arg72Pro) Polymorphism and Prostate Cancer Risk: Association between Disease Onset and Proline Genotype. Pathobiology. 78(4). 193–200. 25 indexed citations

15.

Keck, Bastian, Robert Stoehr, Sven Wach, et al.. (2010). The plasmacytoid carcinoma of the bladder—rare variant of aggressive urothelial carcinoma. International Journal of Cancer. 129(2). 346–354. 80 indexed citations

16.

Keck, Bastian, Burkhard Kneitz, Nadine T. Gaisa, et al.. (2010). Mutational Activation of <i>FGFR3</i> is Not Involved in the Development of Prostate Cancer. Pathobiology. 77(5). 249–252. 6 indexed citations

17.

Keck, Bastian, Robert Stoehr, Sven Wach, et al.. (2010). 923 PLASMACYTOID UROTHELIAL CARCINOMA: RARE VARIANT OF AGGRESSIVE UROTHELIAL CARCINOMA. European Urology Supplements. 9(2). 290–290. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact